Question 1

What is Knight Therapeutics?

Accepted Answer

Knight Therapeutics is a Company.

Question 2

How often does Knight Therapeutics appear in global news?

Accepted Answer

Tracked across 9 news events drawn from 163 articles.

Question 3

When was Knight Therapeutics first tracked by Ergen?

Accepted Answer

First tracked on Mar 31, 2026.

Question 4

When was Knight Therapeutics last mentioned in news?

Accepted Answer

Last active on Aug 20, 2026.

Question 5

What is Knight Therapeutics's current news sentiment?

Accepted Answer

Aggregate sentiment score: 4 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Knight Therapeutics in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 9 events.

Question 7

What is the most recent event involving Knight Therapeutics?

Accepted Answer

Context Therapeutics announces conference presentation, stock options (May 27, 2026, 7 articles).

Question 8

Who is Knight Therapeutics most connected to?

Accepted Answer

Top relationships: United States — Food and Drug Administration, United States — Food and Drug Administration.

Question 9

How did the "Context Therapeutics announces conference presentation, stock options" event impact Knight Therapeutics?

Accepted Answer

Knight Therapeutics announced its presentation at the Jefferies Global Healthcare Conference and granted stock options to a new employee, which could positively impact its visibility and employee retention.

Question 10

How did the "HotSpot Therapeutics Presents IRF5 Data" event impact Knight Therapeutics?

Accepted Answer

Knight Therapeutics presented positive preclinical data for its IRF5 inhibitor program, which could lead to a novel treatment for autoimmune diseases, enhancing its reputation and potential for future investment.

Question 11

How did the "Kuehn Law Investigates Corcept Therapeutics" event impact Knight Therapeutics?

Accepted Answer

Knight Therapeutics is facing a federal securities lawsuit for allegedly failing to disclose concerns from the FDA regarding its drug candidate, relacorilant, which could lead to a rejection of its New Drug Application. This event negatively impacts its stock price and reputation.

Question 12

How did the "Knight Therapeutics launches WYNZORA in Canada" event impact Knight Therapeutics?

Accepted Answer

Knight Therapeutics is the primary actor, launching WYNZORA in Canada, which expands its product portfolio and may drive revenue growth.

Question 13

How did the "Ardelyx Appoints Rajani Dinavahi CMO" event impact Knight Therapeutics?

Accepted Answer

Knight Therapeutics commercializes IBSRELA in Canada, a product developed by Ardelyx.

Question 14

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.